Neurocrine Biosciences INGREZZA Shows Clinically Meaningful Improvement in Tardive Dyskinesia Study

Key Takeaways

• Research published in The Journal of Clinical Psychiatry establishes clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS)
• Study demonstrates patient-reported improvement with INGREZZA (valbenazine) across the KINECT clinical program
• Findings provide healthcare providers with standardized metrics to assess treatment effectiveness in tardive dyskinesia patients

---

Neurocrine Biosciences announced April 29, 2026, that new peer-reviewed research published in The Journal of Clinical Psychiatry has established a clinically meaningful improvement threshold for tardive dyskinesia patients treated with INGREZZA (valbenazine).

The study characterizes patient-reported improvement with INGREZZA across Neurocrine’s KINECT clinical program, focusing on the Tardive Dyskinesia Impact Scale (TDIS). This research provides healthcare providers with standardized benchmarks to evaluate treatment effectiveness in patients suffering from this debilitating movement disorder.

Clinical Significance for Tardive Dyskinesia Treatment

Tardive dyskinesia affects hundreds of thousands of patients who develop involuntary movements as a side effect of certain psychiatric medications. The establishment of clinically meaningful improvement thresholds represents a significant advancement in measuring treatment outcomes beyond traditional physician-assessed scales.

The TDIS focuses on patient-reported outcomes, capturing how tardive dyskinesia impacts daily functioning, social interactions, and quality of life from the patient’s perspective. This patient-centric approach provides a more comprehensive understanding of treatment benefits.

INGREZZA Market Position

INGREZZA, approved by the FDA for tardive dyskinesia treatment, has become a leading therapy in this specialized market. The drug works by selectively inhibiting vesicular monoamine transporter 2 (VMAT2), reducing dopamine release and helping control involuntary movements.

This publication strengthens INGREZZA’s clinical evidence base and may support expanded use in clinical practice. The research comes from Neurocrine’s comprehensive KINECT clinical program, which has generated extensive safety and efficacy data across diverse patient populations.

Implications for Patient Care

The establishment of TDIS improvement thresholds enables more precise treatment monitoring and optimization. Healthcare providers can now use standardized criteria to determine when patients achieve meaningful clinical benefits, potentially leading to better treatment adherence and outcomes.

For Neurocrine Biosciences (NASDAQ: NBIX), this research reinforces INGREZZA’s position in the tardive dyskinesia market while supporting potential label expansions and clinical guideline updates.

---

Frequently Asked Questions

What is the Tardive Dyskinesia Impact Scale (TDIS)?

TDIS is a patient-reported outcome measure that assesses how tardive dyskinesia affects daily functioning, social interactions, and quality of life from the patient’s own perspective, complementing physician assessments.

How does INGREZZA work for tardive dyskinesia?

INGREZZA (valbenazine) selectively inhibits vesicular monoamine transporter 2 (VMAT2), which reduces dopamine release in the brain and helps control the involuntary movements characteristic of tardive dyskinesia.

What makes this research clinically significant?

The study establishes standardized thresholds for measuring clinically meaningful improvement, giving healthcare providers objective criteria to assess treatment effectiveness and optimize patient care in tardive dyskinesia.